A5048822204- Mosquito-borne diseases and control
- Influenza Virus Research Studies
- Viral Infections and Vectors
- SARS-CoV-2 and COVID-19 Research
- Viral Infections and Outbreaks Research
- Vaccine Coverage and Hesitancy
- Malaria Research and Control
- Respiratory viral infections research
- COVID-19 epidemiological studies
- Zoonotic diseases and public health
- Vibrio bacteria research studies
- Animal Disease Management and Epidemiology
- vaccines and immunoinformatics approaches
- Immune Response and Inflammation
- Pneumonia and Respiratory Infections
- Hepatitis B Virus Studies
- Receptor Mechanisms and Signaling
- Health Systems, Economic Evaluations, Quality of Life
- COVID-19 Clinical Research Studies
- Virology and Viral Diseases
- Monoclonal and Polyclonal Antibodies Research
- COVID-19 Impact on Reproduction
- interferon and immune responses
- Healthcare cost, quality, practices
- Insect symbiosis and bacterial influences
Coalition for Epidemic Preparedness Innovations
2020-2023
Sanofi (France)
2008-2017
Institut Mérieux (France)
2012-2015
Clinique Pasteur
2012
Sanofi (Mexico)
2011
Human Immunome Project
2006
Stavanger University Hospital
2006
London Chest Hospital
2000
St. Mary's Hospital
1998
St Mary's Hospital
1998
Developing Covid-19 Vaccines at Pandemic Speed An ideal vaccine platform would support development from viral sequencing to clinical trials in less than 16 weeks, demonstrate elicitation of consist...
A candidate tetravalent dengue vaccine is being assessed in three clinical trials involving more than 35,000 children between the ages of 2 and 16 years Asian-Pacific Latin American countries. We report results long-term follow-up interim analyses integrated efficacy analyses.We are assessing incidence hospitalization for virologically confirmed as a surrogate safety end point during 3 to 6 two phase trials, CYD14 CYD15, 2b trial, CYD23/57. estimated using pooled data from first 25 months...
In light of the increasing rate dengue infections throughout world despite vector-control measures, several vaccine candidates are in development.In a phase 3 efficacy trial tetravalent five Latin American countries where is endemic, we randomly assigned healthy children between ages 9 and 16 years 2:1 ratio to receive three injections recombinant, live, attenuated, (CYD-TDV) or placebo at months 0, 6, 12 under blinded conditions. The were then followed for 25 months. primary outcome was...
ABSTRACT A multiplex reverse transcription (RT)-PCR method that has been developed is capable of detecting and subtyping influenza (H1N1 H3N2) B viruses as well respiratory syncytial virus (RSV) types in clinical samples taken part a national community-based surveillance program influenza-like illness England Wales. The detection each different pathogen depended on distinguishing five amplification products sizes agarose gels following RT-PCR with multiple primer sets. was tested 65...
Background: Despite their potential for increased morbidity, 75% to 90% of asthmatic children do not receive influenza vaccination. Live attenuated vaccine (LAIV), a cold-adapted, temperature-sensitive, trivalent vaccine, is approved prevention in healthy 5 19 years age. LAIV has been studied only small number with asthma. Methods: Children 6 17 age, clinical diagnosis asthma, received single dose either intranasal CAIV-T (an investigational refrigerator-stable formulation LAIV; n = 1114) or...
Background. Enhanced influenza vaccines are needed to provide improved protection for elderly individuals. The intradermal vaccination route was hypothesized immunogenicity superior that provided by the intramuscular route.
OBJECTIVE. The goal was to evaluate the safety, tolerability, and efficacy of an investigational, refrigerator-stable formulation live attenuated influenza vaccine (cold-adapted vaccine-trivalent) against culture-confirmed influenza, acute otitis media, effectiveness outcomes in young children day care over 2 consecutive seasons. METHODS. Children 6 <36 months age who were attending assigned randomly year 1 receive doses or placebo intranasally, 35 ± 7 days apart. In 2, subjects...
Background: Live attenuated influenza vaccine (LAIV; FluMist) is a trivalent containing cold-adapted viruses that infect and replicate in cells lining the nasopharynx to induce immunity. Recovery of (shedding) measured by culture nasal specimens. Shedding not equated with transmission because requires more virus than detected many swabs. Previous studies LAIV did detect close contacts. The primary objective this study was estimate probability placebo contacts day care setting. Methods: One...
The sanofi pasteur tetravalent dengue vaccine candidate is composed of 4 recombinant live attenuated vaccines based on a yellow fever 17D (YFV 17D) backbone, each expressing the prM and envelope genes one four virus serotypes. Pre-clinical studies have demonstrated that TV genetically phenotypically stable, non-hepatotropic, less neurovirulent than YFV does not infect mosquitoes by oral route. In vitro in vivo preclinical also showed induced controlled stimulation human dendritic cells,...
The COVID-19 pandemic accelerated research and innovation across numerous fields of medicine. It emphasized how disease concepts must reflect dynamic heterogeneous interrelationships between physical characteristics, genetics, co-morbidities, environmental exposures, socioeconomic determinants health throughout life. This article explores scientists other stakeholders collaborate in novel, interdisciplinary ways at these new frontiers medicine, focusing on communicable diseases,...